Type III interferons (IFN-λ) are part of the innate immune response to hepatitis C virus (HCV) infection however the specific role of IFN-λ4 and the nature of the viral adaption to this pressure have not been defined. Here we use paired genome-wide human and viral genetic data in 485 patients infected with HCV genotype 3a to explore the role of IFN-λ4 on HCV evolution during chronic infection. We show that genetic variations within the host IFNL4 locus have a broad and systematic impact on HCV amino acid diversity. We also demonstrate that this impact is larger in patients producing a more active form of IFN-λ4 protein compared to the less active form. A similar observation was noted for viral load. We conclude that IFN-λ4 protein is a likely causal agent driving widespread HCV amino acid changes and associated with viral load and possibly other clinical and biological outcomes of HCV infection.
Introduction
Hepatitis C virus (HCV) infects an estimated 71 million people worldwide 1 and can lead to severe liver disease in chronically infected patients. The virus is highly variable and has been classified into 7 distinct genotypes, and further divided into 67 subtypes, based on nucleotide sequence identity 2 . The factors that have driven the evolutionary path of HCV are multifactorial but undoubtedly are also shaped by host genetics. Because of its major health burden, determining how both host and viral genetics contribute to the outcomes of infection is critical for understanding HCVmediated pathogenesis 3 .
Using a systematic genome-to-genome approach in a cohort of chronically infected patients, we recently reported associations between an intronic single nucleotide polymorphism (SNP) rs12979860 in the interferon lambda 4 gene (CC vs. non-CC and herein referred to as IFNL4 SNP or genotypes) and 11 amino acid polymorphisms on the HCV polyprotein 4 . This broad effects was unexpected since IFNL4 is a member of the type III IFN family that act as cytokines as part of the innate immune system and therefore lack apparent epitope specificity 5 .
These associations between polymorphisms on the HCV polyprotein and host IFNL4
genotypes are further intriguing given that variants within the IFNL3/4 locus (including rs12979860 SNP) reportedly contribute to HCV clinical and biological outcomes, including spontaneous virus clearance, response to IFN-based treatment, viral load and liver disease progression [6] [7] [8] [9] [10] [11] [12] [13] . It is possible that the associations between the outcomes of HCV infection and the IFNL3/4 locus are inherently linked to its impact on the viral genome.
The intronic IFNL4 SNP rs12979860 is in high linkage disequilibrium with other SNPs that may be more biologically relevant, including the exonic SNPs rs368234815
(r 2 =0.975 CEU population, 1000 Genomes dataset) in IFNL4 and rs4803217
(r 2 =0.975 CEU population, 1000 Genomes dataset) in IFNL3. The SNP rs368234815
[ΔG>TT] causes a frameshift, abrogating production of IFN-λ4 protein 14 and it is reported that the SNP rs4803217 [G>T] in 3' UTR of IFNL3 influences mRNA stability 15, 16 .
Moreover, an amino acid substitution (coded by the SNP rs117648444 [G>A] ) in the IFN-λ4 protein, which substitutes proline for serine at position 70 (P70 and S70 respectively), reduces its antiviral activity in vitro 17 . Thus, the combination of SNPs rs368234815 and rs4803217 creates three haplotypes, one that does not produce IFN-λ4 protein (TT/G or TT/A; IFN-λ4-Null) and two that result in production of two IFN-λ4 protein variants (ΔG/G; IFN-λ4-P70 and Δ G/A; IFN-λ4-S70). Patients harbouring the impaired IFN-λ4-S70 variant display lower hepatic interferonstimulated gene (ISGs) expression levels, which is associated with increased viral clearance following acute infection and a better response to IFN-based therapy, compared to patients carrying the more active .
In this study, we generated paired whole HCV genomes and genome-wide human SNP data from a cohort of 485 patients with self-reported white ancestry infected with HCV genotype (gt) 3a (411 from the BOSON 19 cohort and 74 from the Expanded Access Programme (EAP) cohort 20 ). We report that IFNL4 genotypes have a widespread impact at polymorphic sites across the entire virus polyprotein. We also find an association with viral nucleotide content and certain dinucleotide frequencies, such as UpA. Finally, we demonstrate that IFN-λ4-S70 and IFN-λ4-P70 have different effect sizes on both viral load and viral amino acids. Together these observations suggest that IFN-λ4 is a major driver of HCV sequence diversity and clinical measures such as viral load.
Results

Viral principal components are associated with host IFNL4 SNP
Paired human and viral genetic data were obtained for 485 HCV genotype 3a
infected patients (N BOSON =411, N EAP =74, Methods). To control for both human and virus population structures, we performed principal component analysis (PCA) using host and viral genetic data separately (Methods). The host PCA defined a largely homogenous group corresponding to the self-reported white ancestry (Supplementary Fig. 1a ). The first and second viral principal components (PCs) explained only 3% and 2% of HCV nucleotide diversity variance respectively ( Supplementary Fig. 1b) , as most of the observed evolution was on terminal branches of the phylogenetic tree (Fig. 1a) . The viral sequences from the two cohorts were non-randomly distributed on the tree 21 and one clade was underrepresented in the EAP cohort sequences (Bayes factor = 249, Methods and Supplementary Fig.   2a ). However, this observation was not reflected in host IFNL4 genotypes, which was randomly distributed on the viral phylogenetic tree (Bayes factor = 1.1, Supplementary Fig. 2b ).
The first two viral PCs were clustered with clades on the virus phylogeny (Fig. 1a) .
The other PCs changed more gradually and were grouped to a lesser degree with specific clades on the tree. To explore any specific role for IFNL4 SNP on viral diversity, we tested whether any viral PCs were associated with IFNL4 genotypes in a univariate analysis and observed that 16 of the 485 viral PCs were nominally associated with IFNL4 genotypes (P<0.05). At a 10% false discovery rate (FDR), the fifth and seventh PCs were associated with IFNL4 genotypes (Fig. 1b-d ) explaining 0.7% and 0.5% of the total variance in the nucleotide sequences ( Supplementary   Fig. 1b) . The nucleotides of codon 2570 had the largest contribution (2.3%) to the fifth PC; this amino acid position was the most associated site with IFNL4 SNP in our previous report (Supplementary Fig. 3 ). We then performed the same analysis in each cohort separately (Supplementary notes). In the BOSON cohort, we observed significant associations between three viral PCs and IFNL4 genotypes ( Supplementary Fig. 4 and 5). In the EAP cohort, none of the viral PCs were significantly associated with IFNL4 genotypes, potentially due to small sample size.
However, projecting the EAP viral sequences into the PCs axes of the BOSON cohort, we could predict IFNL4 genotype in the EAP patients (area under the curve of 6 0.73). This indicated that the EAP viral PCs also carried information about the host genotypes (Supplementary notes and Supplementary Fig. 6 ).
To investigate whether the observed associations between IFNL4 genotypes and viral PCs were due to unaccounted population structure, we selected 500 SNPs across the human genome with frequencies similar to the IFNL4 SNP and tested for association between these SNPs and the viral PCs (Fig. 1b) 
IFNL3/4 locus has a widespread impact on the viral polyprotein
A major advantage of determining entire HCV genomic sequence data is the possibility to perform footprinting analysis at a genome-wide scale. The nucleotide and amino acid frequencies at polymorphic viral sites in the two cohorts were similar and no systematic differences were observed (Supplementary Fig. 7) . We tested the association between IFNL4 genotypes and presence or absence of each amino acid at all variable sites (for amino acids present in at least 20 samples) on the HCV polyprotein, performing 977 tests at 471 sites. We observed that P-values were highly inflated ( Fig. 2a) with a genomic inflation factor (λ) of 2.16. λ is defined as the ratio of the median of the empirically observed distribution of the association test statistic to the expected median, thus quantifying the extent of the bulk inflation in the observed statistic. Generally, an inflated λ value can reflect undetected sample duplications, unknown familial relationships, unaccounted and systematic technical bias and population structure but also potential enrichment in genuine associations.
To ensure that the observed genomic inflation was not due to population structure or some other systematic bias, λ was estimated for the previously 500 selected SNPs (frequency-matched to IFNL4 SNP) performing the same genomic association tests under three different models: without any covariates, including the first two viral PCs as covariates and including the first two viral and the first three host PCs as covariates. Inflation in the P-values was only observed for the IFNL4 SNP and not the other 500 SNPs ( Fig. 2a and Supplementary Fig. 8 ). Moreover including host and viral PCs as covariates had little impact on the results (Supplementary Fig. 8 ). We observed that the λ IFNL4 differed significantly from the distribution of λ under the null hypothesis of no association (estimated using λ s from the 500 frequency-matched SNPs, P=7.08x10 -34 , Fig. 2d ). In the BOSON cohort only analysis, similar results were observed (Supplementary notes and Supplementary Fig. 9 ).
Using the logistic regression association tests including two viral PCs and three host PCs, we found that 9% of variable sites (42/471) were associated with IFNL4 SNP at 5% FDR, increasing to 16% of sites (76/471) at a 10% FDR ( Supplementary Fig. 10 and Supplementary Supplementary Fig. 11 ). ).
The P-values for the association tests between the synonymous codon changes and the IFNL4 SNP were slightly inflated ( Fig. 2c and f To further explore the viral nucleotide association, we estimated the dinucleotide frequencies for the different IFNL4 genotypes (Supplementary Fig. 13 ). The UpA dinucleotide frequency (estimated as the ratio of observed to expected frequencies) was significantly lower in the IFNL4 non-CC group compared to the CC group
). By contrast, the UpG dinucleotide frequency was significantly higher in the IFNL4 non-CC group compared to the CC group (P=1.5x10 Table 3 ).
Since IFN-λ4-S70 can be distinguished phenotypically from IFN-λ4-P70 both in vivo and in vitro, we examined whether the haplotypes had distinct effects on viral amino acid polymorphisms and clinical measures such as viral load. We estimated the effect size of IFN-λ4-S70 and IFN-λ4-P70 relative to the IFN-λ4-Null haplotype on the presence and absence of the 76 amino acids associated with IFNL4 genotypes at 10% FDR. We found that the estimated effect sizes of IFN-λ4-S70 were consistently smaller than those for IFN-λ4-P70 (Fig. 3) . Under the null hypothesis that there is no difference in the effect sizes of IFN-λ4-P70 and IFN-λ4-S70 alleles on viral amino acid polymorphisms, we would expect that the slope of the linear regression line ( ).
We then investigated the effects of IFN-λ4 haplotypes on viral load. For this analysis, the EAP cohort was excluded as these patients had advanced liver disease with consistently lower viral loads relative to the BOSON cohort ( Supplementary Fig. 15 ).
We observed no difference in mean viral load between patients carrying IFN-λ4-S70
and IFN-λ4-Null haplotypes (P=0.61). However the viral load in patients carrying IFN-λ 4-P70 was significantly lower than in the other two groups (P IFN-λ4-S70 =1.6x10 -4 and We used a Bayesian approach to investigate the relationship between the effect sizes of the three IFN-λ4 haplotypes on viral load (Fig. 4b) . In essence, this method weighs up the evidence that the genetic effects of the IFN-λ4-Null, IFN-λ4-S70 and 
Supplementary notes).
Taken together, the combination of IFN-λ4-P70 and S2414
conferred a 2.6-fold decrease in viral load compared to IFN-λ4-S70 and S2414
(mean viral load for IFN-λ4-P70 and S2414=2,376,747 IU/ml, and mean viral load IFN-λ4-S70 and S2414=6,093,167 IU/ml). The posterior probability of the five tested models from (a) stacked on top of each other. Models where the posterior probability is higher or lower than the prior probability are coloured as dark grey and light grey respectively. Only model 3 has a posterior probability bigger than its prior probability and it assumes that the mean viral load is the same in IFN-λ4-Null and IFN-λ4-S70 groups while the mean viral load of IFN-λ4-P70 group is different from them. (c) Viral load stratified by the host IFN-λ4 allele and the presence and absence of serine in the viral amino acid site 2414. The black dots and lines indicate the mean and confidence interval for each group. (d) The posterior probability of the 58 tested models from (c) stacked on top of each other. Models where the posterior probability is higher or lower than the prior probability are coloured as dark grey and light grey respectively. Model 5 has the highest posterior probability and it assumes that the mean viral load is only different in "IFN-λ4-P70 + 2414 serine" group relative to the other groups.
Discussion
Here, we show that genetic variants in the human IFNL4 locus drive sequence change across the entire HCV polyprotein. We also report an association of the IFNL3/4 locus with synonymous codon variants, suggesting that this locus might also affect the HCV genome at the nucleotide level. Finally, we report that IFN-λ4-S70
haplotype has a lesser impact on viral amino acid diversity and viral load compared to the more active IFN-λ4-P70 haplotype indicating that the IFNL4 gene is likely not only a major driver of HCV amino acid variation but also modulates viral load in patients. Our findings extend the association between genetic variation in the IFNL3/4 locus and outcome of HCV infection as well as hepatic disease [6] [7] [8] [9] [10] [11] [12] [13] 18 .
We selected patients chronically infected with HCV genotype 3a and of self-reported white ancestry to limit the impact of human and viral population structures in our analyses. We observed significant associations between the fifth and seventh viral PCs (calculated using viral nucleotides) and host IFNL4 SNP and that the P-values of association study between the host IFNL4 SNP and the virus amino acids across the entire polyprotein were highly inflated. No such association or inflation was observed with 500 SNPs from across the human genome that were frequency-matched to the IFNL4 SNP. This indicated that the observed impact of IFNL4 SNP on the viral sequences was not due to population structure or other systematic bias. We conclude that IFNL4 locus is an important driver of amino acid sequence change of HCV genotype 3a. Our studies provide a landmark for future analysis on whether IFNL3/4 genetic variation also drives diversity in other HCV genotypes and subtypes across other ethnic populations.
To distinguish the effect of IFNL4 SNP on viral amino acid from the nucleotide variability, we investigated the association of the IFNL4 SNP with synonymous and non-synonymous codon changes. IFNL4 SNP association tests with nonsynonymous codon changes had highly inflated P-values, but we also observed a small inflation of P-values with synonymous codon changes. This indicated that although IFNL4 SNP has a widespread impact at the amino acid level, it may also drive nucleotide diversity but to a lesser extent. To further explore the impact of the IFNL4 variants on viral nucleotides, we investigated viral dinucleotide frequencies. (ΔG/TT) and rs117648444 (G/A). Using these data, we found that the IFN-λ4-S70 allele has a consistently smaller effect on viral amino acid variability relative to the IFN-λ4-P70 allele, which correlates with the reduced antiviral activity for IFN-λ4-S70
observed in vitro
17
. Moreover, the mean viral load in IFN-λ4-Null patients is similar to those carrying the IFN-λ4-S70 allele; by contrast, those carrying an IFN-λ4-P70
variant have a reduced viral load, which also correlates with in vitro data. Taken together, these observations reinforce the hypothesis that IFNL4 is a functional gene with a major role in the HCV infection. We conclude that production of IFN-λ4 drives an altered immune response that mediates reduced viral load and increased impact on viral amino acid diversity.
In this study, we demonstrated by large-scale association studies that the IFNL4 gene, a cytokine part of the innate immune response and therefore considered not to have specific effects at the amino acid level, can drive amino acid changes. We report that 4.2% (126/3021) of the HCV polyprotein amino acid are associated with IFNL4 SNP (at a 20% FDR) and that the impact on amino acid variation is spread across the viral polyprotein. In comparison we previously reported that 5% of the HCV polyprotein was associated with HLA class I and II alleles 4 (20% FDR) at the population level. The only other major driver of HCV amino acid variation is the B cell response, which is largely restricted to modifying epitopes on the envelope glycoproteins, in particular E2
27
. Thus, both arms of the adaptive immune system direct selection of amino acids encoded by HCV through pressure on epitopes recognized by T and B cell responses to infection.
Given that we did not observe any enhancement or depletion of association signals in a specific viral protein or in HLA restricted epitopes, we hypothesize that IFN-λ4 may exert its impact through a previously unknown mechanism or at more than one Online methods
Patient cohorts
For this study we used patient data from the BOSON and EAP cohorts. To limit the potential impact of population structure, we restricted the analysis to patients of selfreported white ancestry infected with HCV genotype 3a for which we had obtained both host genome-wide SNP data and full-length HCV genome sequences. In total we have 485 patients in the study, 411 from the BOSON cohort and 74 from the EAP cohort.
Majority of the patients from the BOSON cohort have no or mild liver disease (compensated liver cirrhosis). The EAP cohort on the other hand consists of HCVinfected patients with advanced liver disease, the majority of whom had decompensated cirrhosis.
Host genotyping and imputation
Informed consent for host genetic analysis was obtained from all patients. DNA samples from patients were genotyped using the Affymetrix UK Biobank array, as described elsewhere 4 . Phasing and imputation was performed using SHAPEIT2 34 and IMPUTE2 35 version 2.3.1 using default settings.
Virus sequencing.
RNA was isolated from 500 μ l plasma using the NucliSENS magnetic extraction system (bioMerieux) and collected in 30 μ l of kit elution buffer for storage at -80 °C in aliquots. 1
Libraries were prepared for Illumina sequencing using the NEBNext Ultra Directional De-multiplexed sequence-read pairs were trimmed of low-quality bases using QUASR (v7.0120) 38 and of adaptor sequences using CutAdapt (version 1.7.1) 39 }, and they were subsequently discarded if either the read had less than 50 bases of remaining sequence or if both reads matched the human reference sequence using Bowtie (version 2.2.4) 40 . The remaining read pool was screened against a BLASTn database containing 165 HCV genomes 41 , which covered its diversity both to choose an appropriate reference and to select those reads that formed a population for de novo assembly with Vicuna (v1.3)
42
. The assembly was finished with V-FAT v1.0 (http://www.broadinstitute.org/scientific-community/science/projects/viral-genomics/vfat). The population consensus sequence at each site was defined as the most common variant at that site among all of the patients.
Statistical analysis.
For the viral data, principle component analysis (PCA) was performed on the nucleotide data as follows. Tri-and quad-allelic sites were converted to binary variables. R (version 3.4.3, https://www.r-project.org) was used to perform the PCA using the prcomp function with default settings. Principle component analysis on the human genotype data was performed using flashpca 43 .
Whole-genome viral consensus sequences for each patient were aligned using MAFFT 44 with default settings. This alignment was used to create a maximumlikelihood tree using RAxML 45 , assuming a general time-reversible model of nucleotide substitution under the gamma model of rate heterogeneity. The resulting tree was rooted at midpoint.
We used treeBreaker software 21 (https://github.com/ansariazim/treeBreaker) to measure association between the virus phylogenetic tree and the host IFNL4 SNP and the cohort ID. This software uses a Bayesian model to infer whether the phenotype of interest is randomly distributed on the tips of the tree and to estimate which branches have a distinct distribution of the phenotype of interest from the rest of the tree.
The univariate association between the IFNL4 SNP (CC vs. non-CC) and the viral PCs was tested using logistic regression in R. We used the qvalue function from the qvalue package in R to perform the FDR analysis. As PCA was performed on the viral nucleotide sequences, to estimate the contribution of each codon to each PC, we added the contribution of all variables that were created for the nucleotides of that codon. The contribution of each variable to the PCs was estimated using function get_pca_var from the factoextra package in R.
To predict the host IFNL4 genotypes in the EAP cohort from the viral PCs, we used the BOSON cohort as the training dataset and fit a logistic regression where the IFNL4 genotypes was the response variable and the three viral PCs associated with it in the univariate analysis as the explanatory variables. Next we projected the EAP viral sequences into the same PC axis as the BOSON cohort analysis (using "predict" function in R). Next we used the projected EAP PCs and the estimated model parameters from the BOSON cohort to predict the host IFNL4 genotypes (using "predict" function in R). Finally we used "ROCR" package in R to compare the predicated IFNL4 genotypes to the actual genotypes in the EAP cohort and to calculate the area under the curve for the classifier.
To choose 500 SNPs across the human genome with similar frequency as the IFNL4 To perform meta-analysis of association between IFNL4 SNP and the viral amino acids, the BOSON and EAP cohorts were analysed independently using logistic regression as previously described. We used fixed effects method to perform metaanalysis. To analyse how often the effect sizes are consistent between the two cohorts (Supplementary notes), we used a binomial test. Under the null hypothesis that the effects identified in the BOSON cohort are false positives, we would have expected the direction of the effect in the two cohorts to be the same 50% of the time.
The sites were sorted in increasing P-value order from the BOSON cohort. For each site, we used the most associated amino acid in the BOSON cohort as the target amino acid to get the direction of effect. Increasing the number of sites one at a time,
we counted the number of times that the direction of effect sizes were consistent in the two cohorts and the total number of sites being analysed and used the binomial test with probability of success of 0.5.
To separate the impact of the IFNL4 SNP on amino acids from the nucleotides we investigated the nucleotide sequences at the codon level. At each codon (where there were at least 20 synonymous and 20 non-synonymous codons for the most common codon) we used logistic regression to test for association between IFNL4 SNP (CC vs. non-CC) and the changes from the most common codon to synonymous and non-synonymous codons. The IFNL4 SNP was the response variable and the codons were used as a categorical explanatory variable with three levels. The effect sizes (log(OR)) were estimated for the synonymous and nonsynonymous codons relative to the most common codon. We used two viral PCs and three host PCs as covariates in this analysis.
To calculate the dinucleotide frequencies, the observed proportion of each dinucleotide was normalized by its expected proportion (assuming the nucleotides are independent the expected proportion can be calculated by multiplying the observed proportions for the relevant nucleotides). To test for association with the IFNL4 genotypes we used a linear regression were the normalized dinucleotide proportions were used as the response variable and the IFNL4 genotype as a categorical explanatory variable. We used two viral PCs and three host PCs as covariates.
To estimate the effect of the IFN-λ4 protein variants on the HCV amino acids, we used the 76 sites that were associated with IFNL4 SNP at 10% FDR. Each patient was categorised to one of the three groups; not producing IFN-λ4 (IFN-λ4-Null), producing IFN-λ4-P70 and producing IFN-λ4-S70. We then used logistic regression to estimate the effect sizes (log(OR)) for IFN-λ4-P70 and IFN-λ4-S70 on the virus amino acids relative to the IFN-λ4-Null. The presence and absence of the reported viral amino acid was used as the response variable and the host IFN-λ4 status was used as the explanatory variable with the IFN-λ4-Null used as the base level and the log odds ratios for the IFN-λ4-P70 and IFN-λ4-S70 were estimated relative to the IFN-λ4-Null base level. We included two viral PCs and three host PCs as cofactors to account for possible population structure. To test whether the effect sizes of IFN-λ4
variants on viral amino acids are the same, we used the above estimated effect sizes and fit a linear regression line to it. One viral site was excluded from this analysis as it had unreliable effect size estimate (log(OR) = -17) for the IFN-λ4-S70 variant. Under the null hypothesis that the IFN-λ4-P70 and IFN-λ4-S70 have the same effect sizes, we would expect that the linear regression line to have a slope of one. To test whether the slope of the fitted line is different from one, we used R to fit a linear regression line that goes through the origin and used the offset function (F-test).
To assess the evidence for whether the mean viral load is different in the three patient groups of IFN-λ4-Null, IFN-λ4-P70 and IFN-λ4-S70, we used a Bayesian framework to perform model comparison (see Supplementary notes for further details). The models we considered comprised fixed and independent effects between the IFN-λ4 variants. We standardised the log10(viral load) so that it had a mean of zero and standard deviation of one. We used linear regression to get maximum likelihood estimates of the effects of IFN-λ4-S70 and IFN-λ4-P70 variants relative to the IFN-λ4-Null variant. The estimates were adjusted for cirrhosis status and population structure (including two viral PCs and three host PCs in the regression as covariates). For each effect size we assumed a normally distributed prior on the log(OR) of association with mean of zero. The prior covariance matrix determines the prior model assumptions. The elements of the covariance matrix were chosen such that the relevant prior model is set (see Supplementary notes for details).
To assess the evidence for interaction between host IFN-λ4 variants and viral amino acid site 2414, we used the same Bayesian framework detailed above. The patients were grouped into six categories based on the host IFN-λ4 variants and the presence or absence of serine at viral site 2414. We standardised the log10(viral load) so that it had a mean of zero and standard deviation of one. We used linear regression to get maximum likelihood estimates of the effects of "IFN-λ4-Null + 2414 not serine", "IFN- 
